<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326690</url>
  </required_header>
  <id_info>
    <org_study_id>BioVentrix - Blue Egg Trial™</org_study_id>
    <nct_id>NCT00326690</nct_id>
  </id_info>
  <brief_title>Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity</brief_title>
  <official_title>A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioVentrix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioVentrix</source>
  <brief_summary>
    <textblock>
      The purpose of the present prospective, randomized study is to investigate the clinical&#xD;
      effectiveness of standardized left ventricular reconstruction surgery (LVR). In order to&#xD;
      standardize the procedure, the operation will be performed with the Blue Egg, manufactured by&#xD;
      BioVentrix, a subsidiary of CHF Technologies, Inc.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to test whether a standardized Left Ventricular&#xD;
      Reconstruction (LVR) performed with the Blue Egg device improves cardiopulmonary exercise&#xD;
      capacity in subjects with stable New York Heart Association (NYHA) Class III or IV heart&#xD;
      failure due to ischemic cardiomyopathy with an akinetic or dyskinetic anterior wall. This&#xD;
      shall be accomplished by comparing changes in cardiopulmonary exercise between a group of&#xD;
      subjects treated with LVR and optimal medical therapy (Treatment) to a group treated with&#xD;
      optimal medical therapy alone (Control).&#xD;
&#xD;
      Secondary objectives will examine the difference in heart failure symptoms between the two&#xD;
      groups.&#xD;
&#xD;
      The primary hypothesis is that the average change in peak oxygen consumption (MVO2) observed&#xD;
      in the treatment group from baseline to 6 months post surgery date is at least 1.2 ml&#xD;
      O2/min/kg greater than the average change observed in the control group in the same time&#xD;
      frame.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to recruit and enroll patients&#xD;
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A change in peak oxygen consumption (MVO2) observed in the treatment group from baseline to 6 months post surgery date is at least 1.2 ml O2/min/kg greater than the average change observed in the control group in the same time frame.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives will examine the difference in heart failure symptoms between the two groups.</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blue Egg Device</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be 18 years of age or older&#xD;
&#xD;
          -  Have symptomatic heart failure consistent with NYHA Class III or IV&#xD;
&#xD;
          -  Have been treated, in the opinion of the Principal Investigator, for at least 12 weeks&#xD;
             with an optimized pharmacological regimen, including no substantial dosage titration&#xD;
             for the last 4 weeks. This will typically mean that the subject has had (unless&#xD;
             intolerant) appropriate doses of angiotensin-converting enzyme (ACE) inhibitors,&#xD;
             beta-blockers (β-blockers) and/or aldosterone inhibitors and diuretics.&#xD;
&#xD;
          -  Have a dilated left ventricular (LV) with an LV end-systolic volume index (LVESVI) of&#xD;
             60 ml/m² and an akinetic or dyskinetic anterior wall&#xD;
&#xD;
          -  Have an LV ejection fraction less than or equal to 35%&#xD;
&#xD;
          -  Have an MVO2 of equal to or greater than 10, but equal to or less than 16 ml O2/min/kg&#xD;
&#xD;
          -  Have demonstrated myocardial infarction without viability on a dobutamine stress&#xD;
             echocardiogram in a region considered for surgery. Alternatively, have demonstrated&#xD;
             the same physiological feature with gadolinium/magnetic resonance imaging (MRI)&#xD;
             procedures or other sophisticated methodology for viability assessment.&#xD;
&#xD;
          -  Agree to be compliant with the study protocol and willing and able to return for&#xD;
             follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had a myocardial infarction within 90 days of consent&#xD;
&#xD;
          -  Be inotrope or intra-aortic balloon pump (IABP) dependent&#xD;
&#xD;
          -  Require, in the judgment of the Principal Investigator, cardiac surgery that cannot be&#xD;
             deferred for 6 months, such as subjects with:&#xD;
&#xD;
               -  left main coronary artery disease&#xD;
&#xD;
               -  intractable ventricular arrhythmias&#xD;
&#xD;
               -  Canadian Cardiovascular Society Angina Class III or IV symptoms&#xD;
&#xD;
               -  aortic stenosis or insufficiency requiring replacement&#xD;
&#xD;
               -  3+ or 4+ mitral regurgitation&#xD;
&#xD;
          -  Have any comorbid medical condition that is a contraindication to cardiac surgery&#xD;
             (e.g., renal failure, coagulopathy, severe chronic obstructive pulmonary disease&#xD;
             [COPD], cerebrovascular accident [CVA], prior stroke, known malignancy etc.)&#xD;
&#xD;
          -  Have congestive heart failure (CHF) due to a cause other than ischemic cardiomyopathy&#xD;
&#xD;
          -  Have a history of radiation therapy to the chest or mediastinum&#xD;
&#xD;
          -  Have exercise tolerance limited by a condition other than heart failure&#xD;
&#xD;
          -  Be unable to perform cardiopulmonary stress test&#xD;
&#xD;
          -  Have a history of alcohol abuse, drug addiction, or other psychosocial condition that&#xD;
             would preclude successful participation or realization of benefit from the trial in&#xD;
             the opinion of the Principal Investigator.&#xD;
&#xD;
          -  Be a female of child-bearing age who is pregnant or does not agree to use standard&#xD;
             methods of birth control.&#xD;
&#xD;
          -  Carry a diagnosis of an illness other than CHF with life expectancy less than 12&#xD;
             months.&#xD;
&#xD;
          -  Participating in another trial (other than non-therapeutic or interventional&#xD;
             observation) within the last 30 days or less than 60 days after completion of a heart&#xD;
             failure drug trial.&#xD;
&#xD;
          -  Biventricular pacemaker implantation and/or activation within the past 60 days&#xD;
&#xD;
          -  Percutaneous coronary intervention (PCI) with coronary revascularization within the&#xD;
             last 60 days.&#xD;
&#xD;
          -  More than one prior sternotomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert R. Lazzara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Jorde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis Pagani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D. Bergin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard J Eisen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernst Schwarz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedar Sinai Department of Cardiothoracic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volkmar Falk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariell Jessup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erika Feller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosemary Peterson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital - Tacoma, WA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedar Sinai Department of Cardiothoracic Surgery</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland College of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU College of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia College of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>39 04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002 Jun 13;346(24):1845-53.</citation>
    <PMID>12063368</PMID>
  </reference>
  <reference>
    <citation>Athanasuleas CL, Stanley AW Jr, Buckberg GD, Dor V, DiDonato M, Blackstone EH. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol. 2001 Apr;37(5):1199-209.</citation>
    <PMID>11300423</PMID>
  </reference>
  <reference>
    <citation>Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50.</citation>
    <PMID>15152059</PMID>
  </reference>
  <reference>
    <citation>Cohn JN. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction. Circulation. 1993 Jun;87(6 Suppl):VI1-4.</citation>
    <PMID>8500232</PMID>
  </reference>
  <reference>
    <citation>Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000 Mar 8;283(10):1295-302.</citation>
    <PMID>10714728</PMID>
  </reference>
  <reference>
    <citation>Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar 21;346(12):877-83. Epub 2002 Mar 19.</citation>
    <PMID>11907286</PMID>
  </reference>
  <reference>
    <citation>Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55.</citation>
    <PMID>8614419</PMID>
  </reference>
  <reference>
    <citation>Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8.</citation>
    <PMID>11386263</PMID>
  </reference>
  <reference>
    <citation>Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.</citation>
    <PMID>12668699</PMID>
  </reference>
  <reference>
    <citation>Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.</citation>
    <PMID>10471456</PMID>
  </reference>
  <reference>
    <citation>Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001 Nov 15;345(20):1435-43.</citation>
    <PMID>11794191</PMID>
  </reference>
  <reference>
    <citation>Starling RC, McCarthy PM, Buda T, Wong J, Goormastic M, Smedira NG, Thomas JD, Blackstone EH, Young JB. Results of partial left ventriculectomy for dilated cardiomyopathy: hemodynamic, clinical and echocardiographic observations. J Am Coll Cardiol. 2000 Dec;36(7):2098-103.</citation>
    <PMID>11127447</PMID>
  </reference>
  <reference>
    <citation>Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003 May 28;289(20):2685-94.</citation>
    <PMID>12771115</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 15, 2006</study_first_submitted>
  <study_first_submitted_qc>May 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2006</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Ischemic Cardiomyopathy</keyword>
  <keyword>Idiopathic Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

